These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 12004343)
1. Beneficial effect of lamivudine for hepatitis B transplant recipients. Mutimer D Liver Transpl; 2002 May; 8(5):440-2. PubMed ID: 12004343 [No Abstract] [Full Text] [Related]
2. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406 [TBL] [Abstract][Full Text] [Related]
3. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Chan HL; Chui AK; Lau WY; Chan FK; Hui AY; Rao AR; Wong J; Lai EC; Sung JJ Clin Transplant; 2004 Jun; 18(3):295-300. PubMed ID: 15142051 [TBL] [Abstract][Full Text] [Related]
4. Advances in prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Wang ZF; Zhu ZJ; Shen ZY Hepatobiliary Pancreat Dis Int; 2005 Nov; 4(4):509-14. PubMed ID: 16286253 [TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen. Ahn HJ; Kim MS; Kim YS; Kim SI; Huh KH; Ju MK; Ahn SH; Han KH J Med Virol; 2007 Nov; 79(11):1655-63. PubMed ID: 17854044 [TBL] [Abstract][Full Text] [Related]
6. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Angus PW; Patterson SJ Liver Transpl; 2008 Oct; 14 Suppl 2():S15-22. PubMed ID: 18825721 [TBL] [Abstract][Full Text] [Related]
7. Tenofovir therapy for lamivudine resistance following liver transplantation. Neff GW; Nery J; Lau DT; O'Brien CB; Duncan R; Shire NJ; Ruiz P; Nery C; Montalbano M; Muslu H; Safdar K; Schiff ER; Tzakis AG; Madariaga JR Ann Pharmacother; 2004 Dec; 38(12):1999-2004. PubMed ID: 15507498 [TBL] [Abstract][Full Text] [Related]
8. Prevention of hepatitis B virus recurrence after living donor liver transplantation. Ali H; Egawa H; Uryuhara K; Ogawa K; Kasahara M; Ueda M; Marusawa H; Nabeshima M; Tanaka K Transplant Proc; 2004 Nov; 36(9):2764-7. PubMed ID: 15621143 [TBL] [Abstract][Full Text] [Related]
9. Management of hepatitis B in liver transplant patients. Mohanty SR; Cotler SJ J Clin Gastroenterol; 2005 Jan; 39(1):58-63. PubMed ID: 15599213 [TBL] [Abstract][Full Text] [Related]
10. Management of hepatitis B in liver transplant recipients. Coffin CS; Terrault NA J Viral Hepat; 2007 Nov; 14 Suppl 1():37-44. PubMed ID: 17958641 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of hepatitis B]. Telegdy L Orv Hetil; 2004 Nov; 145(45):2293-6. PubMed ID: 15573894 [TBL] [Abstract][Full Text] [Related]
12. Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Lo CM; Fan ST; Liu CL; Lai CL; Wong J Transplantation; 2003 Feb; 75(3 Suppl):S41-4. PubMed ID: 12589139 [TBL] [Abstract][Full Text] [Related]
13. Cadaveric renal transplantation in hepatitis B antigen-positive recipients using hepatitis B antigen-positive donor organs with lamivudine treatment. Kim JA; Huh W; Lee KW; Kim SJ; Kim YG; Kim DJ; Joh JW; Oh HY Transplant Proc; 2004 Jun; 36(5):1434-7. PubMed ID: 15251352 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis B reactivation in a hepatitis B surface antigen-negative patient after allogeneic bone marrow transplant: successful treatment with lamivudine and seroconversion. Pérez-Grande R; Gutiérrez-Zufiaurre N; Muñoz-Criado S; Blázquez de Castro AM; Vázquez López L; González San Martín F; García Rodríguez JA; Muñoz Bellido JL Diagn Microbiol Infect Dis; 2009 May; 64(1):80-2. PubMed ID: 19304434 [TBL] [Abstract][Full Text] [Related]
15. Lamivudine therapy for hepatitis B infection in post-renal transplant patients: results after 36 months follow-up. de Silva HJ; Herath CA; Sheriff MH Liver Int; 2005 Oct; 25(5):1074-5. PubMed ID: 16162169 [No Abstract] [Full Text] [Related]
16. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy. Gwak GY; Huh W; Lee DH; Choi MS; Lee JH; Koh KC; Kim SJ; Joh JW; Oh HY Transplant Proc; 2007 Dec; 39(10):3121-6. PubMed ID: 18089336 [TBL] [Abstract][Full Text] [Related]
17. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients]. Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179 [TBL] [Abstract][Full Text] [Related]
18. [Hepatitis B: when to use lamivudine?]. Renner EL Schweiz Med Wochenschr; 2000 Jan; 130(1-2):39-41. PubMed ID: 10670046 [No Abstract] [Full Text] [Related]
19. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Hsiao LT; Chiou TJ; Liu JH; Chu CJ; Lin YC; Chao TC; Wang WS; Yen CC; Yang MH; Tzeng CH; Chen PM Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572 [TBL] [Abstract][Full Text] [Related]
20. [Prophylaxsis against recurrance of hepatitis B virus after liver transplantation]. Wu JS; Lu SC; Wang ML; Xia RP; Guo QL; Gao DM; Zhang Y; Liu Y; Li N Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Oct; 22(5):367-9. PubMed ID: 19469177 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]